WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (Nasdaq: IMGN), a leader in the
expanding field of antibody-drug conjugates (ADCs) for the treatment of
cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice
President and Chief Development Officer, is leaving the Company
effective September 2 to pursue an opportunity closer to his primary
residence in Pennsylvania.
"Charlie has made a significant contribution to ImmunoGen over these
past four years," said Mark Enyedy, President and CEO. "He played a key
role in building a strong development organization, including an
experienced team led by our Chief Medical Officer and Vice President,
Anna Berkenblit, MD, and our Vice President, Regulatory Affairs, Theresa
Wingrove, PhD. Anna and Theresa will now report directly to me, as we
advance our pipeline and initiate the Phase 3 study of mirvetuximab
soravtansine before the end of the year. We wish Charlie the very best
in his new role."
"ImmunoGen is successfully implementing a speed-to-market strategy for
our lead product candidate, mirvetuximab soravtansine, is accelerating a
strong pipeline behind it, and continues to drive significant ADC
innovations," commented Dr. Morris. "I am proud of what we have
accomplished with our portfolio and look forward to ImmunoGen's
continued success, as this talented development team advances these
exciting ADC programs to benefit patients with cancer."
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology.
ImmunoGen's lead product candidate, mirvetuximab soravtansine, is
advancing to Phase 3 testing for FRα-positive platinum-resistant ovarian
cancer, with a strong pipeline progressing behind it. ImmunoGen's ADC
technology is used in Roche's marketed product, Kadcyla®, and
in programs in development by partners Amgen, Bayer, Biotest, CytomX,
Lilly, Novartis, Sanofi and Takeda.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005203/en/
Carol Hausner, 781-895-0600
Michael Lampe, 484-575-5040
Source: ImmunoGen, Inc.
News Provided by Acquire Media